HER1-ECD vaccination dispenses with emulsification to elicit HER1-specific anti-proliferative effects.
EGFR (HER1) highlights as one of the most relevant tumor associated antigen in epithelial malignant cells. Monoclonal antibodies and tyrosine kinase inhibitors against EGFR remain as the most advanced approaches in clinical trials. More recently, an active immunotherapy using the HER1 extracellular domain (ECD) adjuvated in very small size proteoliposomes (VSSP) and emulsified in Montanide ISA-51 demonstrated its strength to inhibit tumor cell line proliferation by arresting cells in G(0)/G(1) stage and induction of apoptosis. In this study, we present a simpler HER1-ECD-based formulation, which is lacking the oily component Montanide ISA-51. Generated antibodies following non-emulsive formulation immunization recognized membrane EGFR; avoid EGF and TGFalpha coupling to EGFR leading to a marked abrogation of EGFR phosphorylation levels. Non-emulsive formulation also arrests cell cycle in G(0)/G(1) stage, demonstrating it preserves previous formulation quality in a newer and simpler formulation.
Alpízar
Yeranddy Aguiar
YA
Vaccine Department, Centre for Molecular Immunolgy, Habana, Cuba.
Ramírez
Belinda Sánchez
BS
Fernández
Diana Rosa Hernández
DR
Capote
Ailem Rabasa
AR
Hidalgo
Greta Garrido
GG
Rodríguez
Rolando Pérez
RP
Molina
Luis Enrique Fernández
LE
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000912:Antibodies, Neoplasm / Q000097:blood; D019496:Cancer Vaccines / Q000276:immunology*; D002460:Cell Line; D066246:ErbB Receptors / Q000276:immunology*; D005260:Female; D006801:Humans; D007117:Immunization, Secondary / Q000379:methods; D008081:Liposomes / Q000494:pharmacology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL
D000276:Adjuvants, Immunologic; D000912:Antibodies, Neoplasm; D019496:Cancer Vaccines; D008081:Liposomes; C512478:EGFR protein, human; D066246:ErbB Receptors